View Older Stories View More Recent Stories

Apr 12, 2021 08:00AM Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
Apr 9, 2021 08:02AM Rubius Therapeutics (RUBY) Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors
Apr 9, 2021 08:00AM Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meetin
Apr 9, 2021 08:00AM Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meetin
Mar 15, 2021 07:39AM Rubius Therapeutics (RUBY) Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
Mar 15, 2021 07:38AM Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
Mar 15, 2021 07:38AM Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
Mar 12, 2021 04:30PM Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors
Mar 12, 2021 04:30PM Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors
Mar 10, 2021 04:33PM Rubius Therapeutics (RUBY) to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at AACR
Mar 10, 2021 04:30PM Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meet
Mar 10, 2021 04:30PM Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meet
Feb 23, 2021 08:00AM Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Feb 23, 2021 08:00AM Rubius Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Feb 18, 2021 08:00AM Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Feb 18, 2021 08:00AM Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Feb 9, 2021 08:00AM Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
Feb 9, 2021 08:00AM Rubius Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
Feb 3, 2021 04:45PM Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
Feb 3, 2021 04:45PM Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
Jan 11, 2021 08:07AM Rubius Therapeutics (RUBY) Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
Jan 11, 2021 08:00AM Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
Jan 11, 2021 08:00AM Rubius Therapeutics Provides Operational Update and Outlines 2021 Objectives at the 39th Annual J.P. Morgan Healthcare Conference
Jan 4, 2021 04:01PM Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Jan 4, 2021 04:01PM Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Nov 30, 2020 04:00PM Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
Nov 30, 2020 04:00PM Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
Nov 10, 2020 04:01PM Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Nov 10, 2020 04:01PM Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
Nov 9, 2020 08:05AM Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
Nov 9, 2020 08:05AM Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
Nov 9, 2020 08:00AM Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
Nov 9, 2020 08:00AM Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
Nov 5, 2020 08:00AM Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240
Nov 5, 2020 08:00AM Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240
Oct 29, 2020 04:30PM Rubius Therapeutics to Announce Third Quarter 2020 Financial Results
Oct 29, 2020 04:30PM Rubius Therapeutics to Announce Third Quarter 2020 Financial Results
Oct 28, 2020 06:26AM Rubius Therapeutics (RUBY) Highlights Preclinical Data for RTX-321
Oct 28, 2020 05:00AM Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action
Oct 28, 2020 05:00AM Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action
Oct 15, 2020 08:07AM Rubius Therapeutics (RUBY) Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at SITC
Oct 15, 2020 08:00AM Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
Oct 15, 2020 08:00AM Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting
Sep 29, 2020 04:01PM Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit
Sep 29, 2020 04:01PM Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit
Sep 28, 2020 08:02AM Rubius Therapeutics (RUBY) Appoints Jose Carmona as Chief Financial Officer
Sep 28, 2020 08:00AM Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer
Sep 28, 2020 08:00AM Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer
Sep 8, 2020 04:01PM Rubius Therapeutics to Participate at Upcoming Investor Conferences
Sep 8, 2020 04:01PM Rubius Therapeutics to Participate at Upcoming Investor Conferences
View More Recent Stories View Older Stories